TrialBMC cancer2020

The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors.

Zahra Karimian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.